March 26, 2012
Daiichi Sankyo announced on March 23 that it submitted on the same day a new drug application (NDA) in Japan for the anti-RANKL antibody denosumab (recombinant) for osteoporosis. Denosumab is a fully human monoclonal antibody that targets RANK ligand, an...read more